Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.